Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inhaled corticosteroids + long acting beta agonists
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Inhalation
01
Overview
Inhaled corticosteroids + long acting beta agonists (ICS/LABA) are fixed-dose combination medications delivered via a single inhaler for the management of asthma and chronic obstructive pulmonary disease (COPD). The two components act synergistically to control airway inflammation and bronchoconstriction. Inhaled corticosteroids suppress airway inflammation by modulating gene transcription and reducing inflammatory mediator release. Long-acting beta agonists stimulate β2-adrenergic receptors on airway smooth muscle to induce bronchodilation and also inhibit mast cell mediator release. The combined use improves lung function, reduces exacerbations, enhances quality of life in moderate-to-severe COPD or persistent asthma compared to monotherapy with either agent alone. Commonly used combinations include fluticasone/salmeterol (Advair/Seretide), budesonide/formoterol (Symbicort), and mometasone/formoterol (Dulera). Combination therapy is associated with improved adherence but may increase the risk of pneumonia in some patients[1][2][5][8].
- Brand names
- AdvairSeretideSymbicortDuleraViani
- Other names
- ICS/LABA combination inhalerLABA/ICS combination inhaler
02
Targets
GR (Glucocorticoid receptor)ADRB2 (β2)
Beyond the preview
Go deeper on inhaled corticosteroids + long acting beta agonists.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inhaled corticosteroids + long acting beta agonists.